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Note
The MAF gene is located on chromosome 16q22-q23. Its paralogs MAFA, MAFB and NRL are located on 8q24.3, 20q11.2-q13.1 and 14q11.1-q11.2, respectively. MAF (c-MAF) was first cloned in chicken as the homolog of the founding member of the family, the viral v-MAF gene, encoded by the AS42 retrovirus that induces Musculo Aponeuorotic Fibrosarcoma (M.A.F.) in chicken. The MAF acronym originates from this tumor.
Description
The MAF gene encodes two isoforms generated through alternative splicing. These two protein isoforms are called the MAF short form and MAF long form. The MAF short form is translated from the longest mRNA (mRNA variant#2) encoded by one exon while the longest is encoded by two exons (mRNA variant#1) (see diagram). These two products differ in their carboxy terminal part, the long form containing 30 extra amino-acids. Due to putative alternative polyadenylation signals, other transcripts might encode MAF short form.
Transcription
MAF is expressed in many tissues, but its expression is lineage-specific within a given tissue. For example in T cells, MAF is expressed only in the TH2 lineage.
Protein
Note
The Maf oncoproteins are b-ZIP transcription factors that belong to the AP-1 super-family, which notably includes JUN and FOS. The Maf family contains seven members, which can be subdivided into two subfamilies: the large and small Maf proteins. (TGCTGACTCAGCA and TGCTGACGTCAGCA, respectively). The Extended Homology Region (EHR, also called ancillary domain, which is specific of the Maf proteins, allows them to recognize a longer palindromic sequence than other AP-1 family members. The MARE sequence is composed of a TRE or CRE core (underlined) flanked by a TGC sequence. While the TGC motif is crucial for Maf binding, the TRE/CRE core can be more degenerate. As other large Maf, MAF is posttranslationaly modified by phosphorylation, sumoylation and ubiquitination, mostly occurring in its amino-terminal transactivation domain. Due to posttranslational modifications, notably through GSK3-mediated phosphorylation, MAF apparent molecular weight differs from the calculated one. The protein migrates as different forms ranging from 35 to 50 kDa in SDS-PAGE.
Expression
MAF is expressed in many tissues including neural tissue, kidney and lens. However, its expression is lineage-specific within a given tissue. In T cells for example, MAF is expressed only in the TH2 lineage.
Localisation
MAF is a nuclear protein.
Function
MAF is a transcription factor of the b-Zip family that contacts DNA as homo-or hetero-dimers. MAF knockout mice show peri-natal lethality. They are microphthalmic secondary to defective lens formation. Knockout studies have revealed key roles for MAF in lens terminal differentiation where it regulates the expression of the crystallins, in the specification of the TH2 lineage by regulating the expression of the TH2-specific IL4 cytokine, as well as in chondrocyte terminal differentiation. The role of MAF in lens development is further highlighted by the existence of MAF germinal mutations responsible for congenital cataract in human. Beside its physiological roles, MAF is an oncogene involved in human cancers (see below). 
Homology
Mutations
Germinal
Congenital cataract (see below).
Implicated in
Multiple myeloma
Disease Multiple myeloma (cancer of plasma B cells). Prognosis MAF translocations are of poor prognosis. Cytogenetics t(14;16)(q32;q23).
Abnormal protein
No fusion protein. These translocations lead to the juxtaposition of a strong immunoglobulin enhancer to the MAF promoter leading to its strong ectopic expression. Oncogenesis Large Maf proteins, MAFA, MAFB and MAF/c-MAF, are bona fide oncoproteins as demonstrated in tissue culture, animal models and in human cancer. Their oncogenic activity depends on their ability to act as transcription factors, relies on overexpression and does not require activating mutations (no such mutations have been found in human cancers), although it can be enhanced by point mutation. It is noteworthy that the transforming activity of Maf proteins is contextdependent. It is regulated by post-translational modifications, notably phosphorylation. They can occasionally display tumor suppressor-like activity in specific cellular settings. In embryonic fibroblasts, MAFA displays the strongest transforming activity. Its transforming activity depends on its phosphorylation by GSK3. In human, MAF/c-MAF, MAFB and MAFA genes are translocated to the immunoglobulin heavy chain (IgH) locus in 8-10% of multiple myelomas (MM). These translocations lead to overexpression through a strong enhancer effect without any alteration in their coding sequence. MAF translocations are present in 5% of MM. Beside these translocations, MAF is overexpressed in 50% of MM through an unknown mechanism. MAF overexpression plays a causative role in MM by promoting proliferation through cyclinD2 (CCND2) induction. It also promotes the pathological interactions of bone marrow stroma with cancer cells by enhancing integrin B7 (ITGB7) expression. These pathological cellular interactions lead to increased production of the angiogenic cytokine VEGF. MAF also activates the Ser/Thr AKT activity by inducing the expression of DEPTOR (DEPDC6), an inhibitor of mTORC1 and mTORC2 complexes. While MM is associated with osteolytic lesions, patients with MAF deregulation show low incidence of bone disease. This observation is correlated with low expression by MAF-expressing myeloma cells of DKK1, a Wnt antagonist associated with bone disease in MM. Chemical screens have identified glucocorticoids as potential therapeutical agents that target MAF activity through ubiquitin dependent degradation.
Angioimmunoblastic T cell lymphoma
Prognosis Not determined. Oncogenesis MAF has been shown to be overexpressed in 60% of angioimmunoblastic T cell lymphoma. The mechanisms underlying these deregulations are unknown. Although its causative role has not been demonstrated, its deregulation, as in multiple myeloma, is associated to that of CCND2 and ITGB7. MAF has also been found overexpressed in diverse human T cell lymphomas. Accordingly, MAF overexpression in the T cell compartment leads to T cell lymphoma associated with CCND2 and ITGB7 overexpression in transgenic mice.
Congenital cataract
Disease
In human, the MAF gene is mutated in congenital cataract that could be associated with microcornea or colomboma. These heterozygote point mutations correspond to residues located in the DNA binding domain and appear to be dominant. They disrupt DNA binding activity by targeting the different conserved basic residues R288P, K297R and R299S. Another mutation in the leucine zipper dimerization domain (K320E) was reported. In support for a role of MAF in congenital cataract, knockout studies in mice have demonstrated an important role of MAF during lens development. Moreover, heterozygote point mutants of murine MAF in its transactivation (D90V) or basic domain (R291Q, corresponding to human residue R294) lead to cataract in mice.
